Polyclonal Antibody to Complement Component 5a (C5a)
- Product No.PAA388Po01
- Organism SpeciesSus scrofa; Porcine (Pig) Same name, Different species.
- SourcePolyclonal antibody preparation
- Ig Type IgG
- PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
- Immunogen RPA388Po01-Recombinant Complement Component 5a (C5a)
- Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
- Organism Species Moren/a
- ApplicationsWB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
200µl 1ml 10ml
For more details, please contact local distributors! US$ 252 FREE TRIAL
For more details, please contact local distributors! US$ 360 FREE TRIAL
For more details, please contact local distributors! US$ 900 FREE TRIAL
For more details, please contact local distributors! US$ 3600 FREE TRIAL
For more details, please contact local distributors!
The antibody is a rabbit polyclonal antibody raised against C5a. It has been selected for its ability to recognize C5a in immunohistochemical staining and western blotting.
Western blotting: 0.5-2µg/mL
Optimal working dilutions must be determined by end user.
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for one year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
|Molecular Immunology||Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro ScienceDirect: S0161589011008297|
|Journal of Reproductive Immunology||Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia PubMed: 23415845|
|The Journal of Clinical Investigation||Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis PubMed: PMC3195471|
|Journal of Antimicrobial Chemotherapy||Efficacy of a synthetic antimicrobial peptidomimetic versus vancomycin in a Staphylococcus epidermidis device-related murine peritonitis model Pubmed: 23645587|
|Journal of Orthopaedic Research||Conversion from external fixator to intramedullary nail causes a second hit and impairs fracture healing in a severe trauma model Pubmed: 23070742|
|SpringerPlus||Therapeutic effects of sesame oil on monosodium urate crystal-induced acute inflammatory response in rats Pubmed: 24353977|
|American Journal fo Reproductive Immunology||Evaluation of the Markers of Inflammation in the Umbilical Cord Blood of Newborns of Mothers with Thrombophilia Pubmed:25209155|
|Gynecol Obstet Invest||Complement Split Products C3a/C5a and Receptors: Are They Regulated by Circulating Angiotensin II Type 1 Receptor Autoantibody in Severe Preeclampsia? PubMed: 26485247|
|Journal of Neuroimmunology||Acute and prolonged complement activation in the central nervous system during herpes simplex encephalitis Pubmed:27235358|
|International Immunopharmacology||Consistency and pathophysiological characterization of a rat polymicrobial sepsis model via the improved cecal ligation and puncture surgery Pubmed:26802602|
|Digital Repository||Dosagem de frações ativadas do sistema complemento em empiema induzido em ratos 10183|
|Environmental Pollution||Cadmium-induced immune abnormality is a key pathogenic event in human and rat models of preeclampsia pubmed:27511439|
|Catalog No.||Related products for research use of Sus scrofa; Porcine (Pig) Organism species||Applications (RESEARCH USE ONLY!)|
|RPA388Po01||Recombinant Complement Component 5a (C5a)||Positive Control; Immunogen; SDS-PAGE; WB.|
|PAA388Po01||Polyclonal Antibody to Complement Component 5a (C5a)||WB; IHC; ICC; IP.|
|SEA388Po||ELISA Kit for Complement Component 5a (C5a)||Enzyme-linked immunosorbent assay for Antigen Detection.|